1. Schulak JA. Steroid immunosuppression in kidney transplantation: a passing era. J Surg Res 2004;117(1):154-62.
2. Fauci AS. The effect of hydrocortisone on the kinetics of nor¬mal human lymphocytes. Blood 1975;46:235-243.
3. Almawi WY, Hadro ET, Strom TB. Evidence that glucocorti-costeroid-mediated immunosuppressive effects do not invol¬ve altering second messenger function. Transplantation 1991;52:133-140.
4. Vacca A, Felli MP, Farina AR et al. Glucorticoid receptor-mediated suppression of the interleukin-2 gene expression thro¬ugh impairmant of the cooperativity between nuclear factor of activated T cells and AP-1 enhancer elements. J Exp Med 1992;175:637-646.
5. Barnes PJ, Adcock I, Anti-inflammatory actions of steroids: mo¬lecular mechanisms. Trends Pharmacol Sci 1993;14:436-441.
6. Scheinman RI, Gualberto A, Jewell CM, et al. Characterizati¬on of mechanisms involved in transrepression of NF-kB by activated glucocorticoid receptors. Mol Cell Biol 1995;15:943-953.
7. Knudsen PJ, Dinarello CA, Strom TB. Glucocorticoids inhibit transplantational and post-transcriptional expression of inter-
leukin-1 in U937 cells. J Immunol 1987;39:4129-4134.
8. Zanker B, Walz G, Wieder KJ, et al. Evidence that glucocor-ticoids block expression of the human interleukin-6 gene by accessory cells. Transplantation 1990;183-188.
9. Waage A, O. Bakke O. Glucocorticoids suppress the produc-
Steroid Toxicity and Mycophenolate Mofetil Therapy in Renal Transplant Patients
tion of tumor necrosis factor by lipopolysaccharide-stimula-ted human monocytes. Immunology 1998;68:299-302.
10. Vacca A, Martinotti S, Screpanti I et al. Transcriptional regu¬lation of the interleukin-2 gene by glucocorticoid hormones. J Biol Chem 1990;265:8075-8080.
11. Arya SK, Wong-Staal, Gallo RC. Dexamethosone-mediated inhibition of human T cell growth factor and Â-interferon messenger RNA. J Immunol 1984;133:273-276.
12. Lerut JP. Avoiding steroids in solid organ transplantation. Transpl Int 2003;16(4):213-224.
13. Veenstra DL, Best JH, Hornberger J, et al. Incidence and long-term cost of steroid-related side effects after renal trans¬plantation. Am J Kidney Dis 1999;33:829-839.
14. Land W, Vincenti F. Toxicity-sparing protocols using mycop-henolate mofetil in renal transplantation. Transplantation 2005;80(2 Suppl):221-34.
15. Gosio B. Sperimentate su culture pure di bacilli del carbonc-hio demonstrarano notevole potere antisettica. C R Acad Med
Torino 1893;61:484-489.
16. Franklin TJ, Cook JM. The inhibition of nucleic acid synthe¬sis by mycophenolic acid. Biochem J 1969;113:515-524.
17. Sollinger HW. Mycophenolates in transplantation. Clin Trans¬plant 2004;18(5):485-92.
18. Carr SF, Papp E, Wu JC, et al. Characterization of human type
I and type II IMP dehydrogenases. J Biol Chem 1993;268:272-
286.
19. Eugui EM, Almquist SJ, Muller CD, et al. Lymphocyte-selecti¬ve cytostatic and immunosuppressive effects of mycopheno-lic acid in vitro: role of deoxyguanosine nucleotide depleti¬on. Scand J Immunol 1991;33:161-173.
20. Allison AC, Eugui EM. Mechanisms of action of mycopheno-late mofetil in preventing acute and chronic allograft rejecti¬on. Transplantation 2005;80(2 Suppl):181-90.
21. Bullingham RE, Nicholls AJ, Kamm BR. Clinical pharmacoki-netics of mycophenolate mofetil. Clin Pharmacokinet
1998;34:429-455.
22. Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients.
Transplantation 1995;60:225-232.
23. European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combi¬ned with cyclosporine and corticosteroids for prevention of acute rejection. Lancet 1995;345:1321-1326.
24. Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophe-nolate mofetil for the prevention of acute rejection in cadave¬ric renal transplantation. Transplantation 1996;61:1029-1037.
25. Halloran P, Mathew T, Tomlanovich S, Groth C, Hooftman L, Barker C for the International Mycophenolate Mofetil Renal Transplant Study Groups. Mycophenolate mofetil in renal al-lograft recipients: a pooled efficacy analysis of three rando¬mized, double-blind, clinical studies in prevention of rejecti¬on. Transplantation 1997;63:39-47.
26. Ahsan N, Hricik D, Matas A, et al. Prednisone withdrawal in kidney transplant recipients on cyclosporine and mycophe-
nolate mofetil—a prospective randomized study. Steroid With¬drawal Study Group. Transplantation 1999;68:1865-1874.
27. Kasiske BL, Chakkera HA, Louis TA, et al. A meta-analysis of immunosuppression withdrawal trials in renal transplantati¬on. J Am Soc Nephrol 2000;11:1910-1917.
28. Pascual J, Quereda C, Zamora J, et al. Steroid withdrawal in renal transplant patients on triple therapy with a calcineurin inhibitor and mycophenolate mofetil: a meta-analysis of ran¬domized, controlled trials. Transplantation 2004;78:1548-
1556.
29. Squifflet J-P, Vanrenterghem Y, van Hooff JP et al. and the European Tacrolimus/MMF Transplantation Study Group. Sa¬fe withdrawal of corticosteroids or mycophenolate mofetil: results of a large, prospective, multicenter, randomized
study. Transplant Proc 2002;34:1584-1586.
30. Vanrenterghem Y, Lebranchu Y, Hene R, et al. Double-blind comparison of two corticosteroid regimens plus mycopheno-late mofetil and cyclosporine for prevention of acute renal al-
lograft rejection. Transplantation 2000;70(9):1352-1359.
31. Puig I, Mari JM on behalf of the Spanish Group of the Cell-Cept Study. Induction treatment with mycophenolate mofetil, cyclosporine, and low-dose steroids with subsequent early withdrawal in renal transplant patients: results of the Spanish
Group. Transplant Proc 1999;31:2256-2258.
32. Smak Gregoor PJ, de Sevaux RGL, Ligtenberg G et al. With¬drawal of cyclosporine or prednisone six months after kid¬ney transplantation in patients on triple drug therapy: a ran¬domized, prospective, multicenter study. J Am Soc Nephrol
2002;13:1365-1373.
33. Sola E, Alferez MJ, Cabello M et al. Low-dose and rapid ste¬roid withdrawal in renal transplant patients treated with tac-rolimus and mycophenolate mofetil. Transplant Proc
2002;34:1689-1690.
34. Matas AJ, Ramcharan T, Paraskevas S, et al. Rapid disconti¬nuation of steroids in living donor kidney transplantation: a
pilot study. Am J Transplant 2001;1:278-283.
35. Khwaja K, Asolati M, Harmon J, et al. Outcome at 3 years with a prednisone-free maintenance regimen: a single-center experience with 349 kidney transplant recipients. Am J Trans¬plant 2004;4:980-987.
36. Vincenti F, Monaco A, Grinyo J, et al. Multicenter randomi¬zed prospective trial of steroid withdrawal in renal transplant recipients receiving basiliximab, cyclosporine microemulsion and mycophenolate mofetil. Am J Transplant 2003;3:306-311.
37. Ter Meulen CG, van Riemsdijk I, Hene RJ, et al. Steroid-with¬drawal at 3 days after renal transplantation with anti-IL-2 re¬ceptor [alpha] therapy: a prospective, randomized, multicen-
ter study. Am J Transplant 2004;4:803-810.
38. Rostaing L, Cantarovich D, Mourad G, et al. Corticosteroid-Free Immunosuppression with Tacrolimus, Mycophenolate Mofetil, and Daclizumab Induction in Renal Transplantation.
Transplantation 2005;79:807-814.
39. Land W, Vincenti F. Toxicity-sparing protocols using mycop-henolate mofetil in renal transplantation. Transplantation
2005;80(2 Suppl):S221-34.
Thank you for copying data from http://www.arastirmax.com
